Hemostasis Diagnostics

Focus
D-Dimer Essentials

werfen

Hemostasis Diagnostics

Focus
D-Dimer Essentials

Index

5 Introduction

7 Speaker Information

Session 1
9 **Where does D-Dimer come from and how is it measured**

Session 2
10 **What is venous thromboembolism and the process of exclusion of the diagnosis**

Session 3
11 **Predictive value of VTE recurrence and optimal duration of anticoagulant treatment**

Session 4
12 **Disseminated intravascular coagulation (DIC) Diagnosis and Monitoring**

Session 5
13 **Covid 19 and D-Dimer**

14 The EEMEA Learning Center


ACL TOP 550
Quality Approved Component
ACL TOP Cuvettes
Quality Approved Comp

Introduction

Hemostasis is a complex process that the body uses to stop bleeding when a blood vessel is damaged. It involves a series of chemical reactions that ultimately lead to the formation of a clot, which helps to seal the damaged vessel and prevent further bleeding. The process of coagulation is activated by the presence of injury or damage to a blood vessel and is regulated by several different proteins and enzymes, including fibrinogen, thrombin, and platelets.

One of the key markers in the coagulation process is D-Dimer, a small protein fragment that is produced when a clot is broken down by the body. D-Dimer levels can be measured in the blood, and an elevated level can be a sign of a clot, such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
However, it is important to note that D-Dimer can also be elevated in other conditions such as cancer, trauma, or pregnancy, so it is important to consider the patient's medical history, symptoms, and other test results when interpreting D-Dimer levels.

D-Dimer test is often used in conjunction with other diagnostic methods like ultrasonography for DVT or CT angiography for PE to make a more accurate diagnosis. It is also used as a rule-out test, a negative D-Dimer test is helpful in ruling out the presence of a clot.

In summary, coagulation is a complex process that the body uses to stop bleeding, and D-Dimer is a protein fragment that is produced when a clot is broken down. Elevated levels of D-Dimer can indicate the presence of a clot, but other factors must also be considered when interpreting test results. D-Dimer test is commonly used as a screening tool for thrombotic disorders but also as a rule-out test, and when used in conjunction with other diagnostic methods it can provide a more accurate diagnosis.

Throughout this series Prof. Armando Tripodi will share information about the essentials related to D-Dimer.

Stay Safe and Take Care of Each Other
Werfen EEMEA Hemostasis Team.


werfen

Speaker Information

Professor Armando Tripodi is a leading hemostasis researcher based in Milan, Italy. He received his university degree from the University of Milan and completed his residency in Laboratory Medicine at the same institution. Throughout his career, Professor Tripodi has made significant contributions to the field of Hemostasis and Thrombosis. His research focuses on the molecular and cellular mechanisms of blood coagulation and the development of new diagnostic and therapeutic approaches for thrombotic disorders. He has published over 450 peer-reviewed articles in leading journals and is an invited speaker at international conferences.

Professor Tripodi was full professor of Clinical Biochemistry at the State University in Milano and currently serves as a full professor of Clinical Biochemistry at the Humanitas University in Milano. He also serves as the responsible of the Reference Standardization Laboratory within the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milano. In addition, he is a member of several professional national and international societies and serves on the editorial board of several journals.

In addition to his research and academic responsibilities, Professor Tripodi also provides laboratory care to patients with thrombotic or Hemostasis disorders and actively participates in educational events in the field of Thrombosis and Hemostasis across the world.

Session 1
Where does D-Dimer come from and how is it measured

D-Dimer is a protein fragment that is produced when blood clots are broken down by the body. Elevated levels of D-Dimer in the blood are a sign of increased clotting activity, which can suggest the presence of a blood clot.

To diagnose elevated D-Dimer levels, a laboratory test called a D-Dimer assay is performed. There are several types of D-Dimer assays available, including ELISA, latex agglutination, and rapid quantitative tests.

ELISA (Enzyme-Linked ImmunoSorbent Assay) is a common method used to measure D-Dimer levels. It uses antibodies that specifically recognize and bind to D-Dimer, allowing for a highly sensitive and specific measurement. It is, however, time consuming.

Latex agglutination assays are rapid tests that can provide results in just a few minutes. These tests use latex particles that are coated with antibodies that specifically bind to D-Dimer. When D-Dimer is present in a sample, it causes the latex particles to clump together, which can be detected visually (qualitative results) or with the help of a dedicated equipment (quantitative results).

It is important to note that a positive D-Dimer test result does not necessarily mean that a person has a blood clot or a clotting disorder. Elevated levels of D-Dimer can be seen in many other conditions, such as inflammation, trauma, cancer, old age, etc. Further testing, such as a CT scan or ultrasound, may be necessary to confirm the presence of a clot or to determine the cause of elevated D-Dimer levels.

In this first session of the D-Dimer Essentials series, Professor Armando Tripodi will share with us the formation of D-Dimer and the techniques to measure it.

WATCH THE SESSION NOW

Session 2

What is venous thromboembolism and the process of exclusion of the diagnosis

In the second session of the D-Dimer Essentials series we will review what is Venous thromboembolism (VTE) and the process of exclusion of the diagnosis. VTE refers to a condition where a blood clot forms in the deep veins of the body, often in the legs. These clots can dislodge and travel to the lungs, causing a potentially life-threatening condition known as pulmonary embolism. VTE is a serious medical condition that affects millions of people each year and can result in significant morbidity and mortality if not diagnosed and treated promptly.

The process of excluding a diagnosis of VTE involves a combination of clinical assessment and laboratory testing. The first step is to take a thorough medical history and perform a physical examination to identify any risk factors for VTE and to assess for any signs and symptoms of the condition. This may include swelling or pain in the legs, shortness of breath, chest pain, or a rapid or irregular heartbeat.

If VTE is suspected, further testing is required to make conclusive diagnosis. This may include a blood test called a D-Dimer assay, which measures the levels of a protein fragment that is produced when blood clots are broken down. Elevated levels of D-Dimer in the blood indicates increased clotting activity and suggests the presence of a blood clot. Imaging tests, such as ultrasound or CT scan, may also be performed to visualize the veins and to confirm the presence of a clot.

It is important to exclude a diagnosis of VTE as soon as possible, as this condition can result in significant morbidity and mortality if left untreated. A prompt and accurate diagnosis is essential to ensure that appropriate treatment can be initiated and to prevent any potential complications from the condition.

WATCH THE SESSION NOW

Session 3

Predictive value of VTE recurrence and optimal duration of anticoagulant treatment

Anticoagulation therapy with Warfarin or direct oral anticoagulants (DOACs) are commonly used for the treatment or prophylaxis of venous thromboembolism (VTE) and other cardiovascular diseases. Warfarin works by blocking the action of vitamin K, which is required to produce certain clotting factors in the blood. By reducing the production of these clotting factors, Warfarin helps to prevent the formation of new clots and to reduce the risk of recurrence of VTE. In contrast with Warfarin, DOACs inhibit specifically and directly activated coagulation factors.

The management of patients on Warfarin therapy involves regular monitoring of the patient's international normalized ratio (INR), which is a measure of the clotting time of the blood. The target INR for VTE treatment varies depending on the patient's individual circumstances, but typically ranges between 2.0 and 3.0. DOACs can be given at a fixed dosage, based on patients' characteristics, but measurement of plasma concentrations may be useful in special situations.

D-Dimer testing can play an important role for the prediction of the risk of recurrent event after a first episode of VTE. Studies have shown that patients with persistent elevated D-Dimer may be at risk of recurrent VTE. D-Dimer testing may also be useful to make decision to continue or stop treating patients with Warfarin after the regular course of prophylaxis following a first event. Interventional studies showed that patients with persistently high levels of D-Dimer after discontinuation of Warfarin may benefit from extended Warfarin anticoagulation. Presently, it is unknown whether the same is valid for patient treated with DOACs.

In the third session of the D-Dimer Essentials series we will review when D-Dimer testing can play an important role in the decision to continue or stop treating patients with Warfarin for VTE.

WATCH THE SESSION NOW

Session 4

Disseminated intravascular coagulation (DIC) Diagnosis and Monitoring

Disseminated intravascular coagulation (DIC) is a complex and potentially life-threatening clotting disorder in which abnormal clotting and bleeding occur simultaneously in small blood vessels throughout the body. DIC is a secondary condition that results from an underlying disease, such as cancer, sepsis, or trauma, and can lead to serious complications, including organ failure and death.

The hallmark of DIC is the formation of small blood clots in the tiny blood vessels throughout the body, which can cause blockages and restrict blood flow to vital organs, such as the heart, lungs, brain, and kidneys. At the same time, DIC can cause bleeding into the skin, mucous membranes, and organs, due to the breakdown of the clots and the consumption of clotting factors.

In DIC, the elevated levels of D-Dimer may reflect the ongoing clotting and clot breakdown that is occurring throughout the body. The measurement of D-Dimer levels is an important tool for the diagnosis, monitoring the progression and effectiveness of the treatment of DIC.

The treatment of DIC involves addressing the underlying cause of the condition and providing supportive care to manage the symptoms of clotting and bleeding which may include anticoagulant therapy to prevent the formation of new clots, and blood transfusions to replace the clotting factors that have been consumed.

In the fourth session of the D-Dimer Essentials series we will review the importance of D-Dimer as a biomarker for the diagnosis and monitoring of disseminated intravascular coagulation (DIC), a potentially life-threatening clotting disorder and help guide the management and treatment of the condition.

WATCH THE SESSION NOW

Session 5
Covid 19 and D-Dimer

Coagulopathy, or abnormal blood clotting, is a well-known complication of COVID-19. The virus is thought to trigger an overactive immune response that leads to inflammation and abnormal clotting, which can result in serious complications such as stroke, deep vein thrombosis (DVT), and pulmonary embolism.

One of the biomarkers used to diagnose coagulopathy in COVID-19 is D-Dimer. D-Dimer levels are therefore an important tool for doctors to diagnose and monitor the progression of coagulopathy in COVID-19 patients.

D-Dimer levels can also be elevated in other conditions, such as cancer and sepsis, so it is not a specific indicator for COVID-19 coagulopathy. It should be used in conjunction with other diagnostic tests and imaging solutions to confirm the presence of blood clots.

While not all COVID-19 patients will develop coagulopathy, the risk of developing coagulopathy is higher in patients with severe COVID-19, older adults, and those with underlying health conditions, such as obesity and diabetes. Early recognition and treatment of coagulopathy is critical to preventing serious complications, and regular monitoring of D-Dimer levels can help healthcare providers to quickly identify and intervene in patients who are at risk.


In this last session of the D-Dimer Essentials series, Professor Armando Tripodi will share an overview of the coagulopathy in COVID-19 and the role of D-Dimer as a biomarker for diagnosing and monitoring the progression of the condition in combination with other laboratory and clinical information so that healthcare providers can take a comprehensive approach to diagnosis and treating coagulopathy in COVID-19 patients.

WATCH THE SESSION NOW

The complete D-Dimer Essentials Series is available on the **EEMEA LEARNING CENTER**

Interested in Specialized Diagnostics in the areas of Hemostasis, Acute Care Diagnostics, or Autoimmunity?

Join the EEMEA LEARNING CENTER, our platform of easily accessible scientific content!



Direct access to a selection of scientific webinars and literature at any time!


Login or register on the homepage to let the learning begin!

VISIT
THE WEBSITE

Go under the section of your interest to access directly
a selection of the most relevant scientific articles and webinars.




Hemostasis section:




Content related to Hemostasis conditions like:
- Thrombotic Thombocytopenic Purpura
- Heparin Induced Thrombosis
- Anticoagulation monitoring
- Inherited Bleeding Disorders
- Thrombophilia and more...

Acute Care section:



Content related to Acute Care conditions like:
- Bleeding management
- Antiplatelet Therapy monitoring
- Blood Gas testing in Emergency Department, ICU, Operating Room, and Interventional Procedures

Autoimmunity section:



Content related to Autoimmune conditions like:
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Autoimmune Gastritis
- Antiphospholipid Syndrome
and many more...

DD.Essentials - Rev.0 - All rights reserved - 04/23